FDA Clearance For DVS(R)-HFT, Next-Generation Wireless Sensor To Measure Actual Radiation Dose At Breast And Prostate Tumor Site

Sicel Technologies, Inc. announced it has received clearance from the U.S. Food and Drug Administration to begin marketing DVSĀ®-HFT, the next-generation of the company’s original DVS (Dose Verification System) wireless implantable dosimeter that remains the only device to measure actual radiation dose at the tumor site for use in treating breast and prostate cancer patients […]

Urologic Oncology Institute Launched To Offer Multi-Disciplinary Care, Personalized Treatments To Patients

UCLA has launched a first-of-its-kind, patient-centered institute dedicated to developing leading-edge therapies for the treatment of kidney, bladder, testicular and prostate cancers. The Institute of Urologic Oncology at UCLA challenges the traditional model of academic departments operating independently of each other, bringing a multi-disciplinary team of scientists and physicians together as part of one cohesive […]

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors (except in the case of […]

Researchers ID Gene Involved In Pancreatic Cancer

Researchers from the University of Michigan Comprehensive Cancer Center have identified a gene that is overexpressed in 90 percent of pancreatic cancers, the most deadly type of cancer. Expression of the gene, Ataxia Telangiectasia Group D Complementing gene, called ATDC, is on average 20 times higher in pancreatic cancer cells than in cells from a […]

Making Prostate Cancer Matter, UK

Making Prostate Cancer Matter – Survey Reveals That Majority Of People Unaware That Men Diagnosed With The Most Common Cancer Subject To Injustice People across the UK are still unaware that men living with prostate cancer – the most common cancer in men – continue to have to deal with the ‘historical legacy of neglect’ […]

Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refractory Prostate Cancer

Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL. AT-101, an oral, pan-Bcl-2 inhibitor currently in double-blinded, randomized Phase II […]

Phase II Study Shows That ZD4054 Could Improve Survival For Hormone Resistant Prostate Cancer (HRPC) Patients With Bone Metastases

A novel compound in development by AstraZeneca as an oral tablet for hormone resistant prostate cancer (HRPC), ZD4054, could improve overall survival (OS) in men with metastatic HRPC, according to Phase II data published today in European Urology.[1] Men with advanced prostate cancer may receive initially effective treatment with hormonal therapies to which the majority […]

2008 Prostate Cancer Retreat Available Online – Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) has made presentations from its 2008 Scientific Retreat available online. The PCF’s annual retreat provides a forum to review advances in prostate cancer research aimed at reducing death and suffering from this prevalent men’s disease. The three-day event was held in October at Incline Village, Nevada, and was attended by […]

Jefferson Scientists Find Protein Potential Drug Target For Treatment-resistant Prostate Cancer

Scientists at Jefferson’s Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely […]

Does Androgen-Deprivation Therapy Accelerate The Development Of Frailty In Older Men With Prostate Cancer? A Conceptual Review (p NA)

UroToday.com- Frailty in the geriatric field is defined as >3 of the following; unintentional weight loss >10 pounds in the past year, weakness measured by grip strength, slow walking speed, self-reported exhaustion, and low physical activity. Many of these toxicities occur in men receiving androgen-deprivation therapy (ADT) for prostate cancer (CaP). In addition, biomarkers such […]